Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood thinner edoxaban studied in patients 80 and older with irregular heartbeat

NCT ID NCT05804747

Knowledge-focused Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how safe and effective the blood thinner edoxaban is for preventing strokes in people aged 80 or older with a common heart rhythm problem called atrial fibrillation. Researchers followed over 1,200 patients in Korea who were already prescribed edoxaban by their doctors. The goal was to gather real-world information on bleeding risks and stroke prevention in this older group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,204 people

The number who actually took part.

Started

Feb 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include participants who are prescribed with edoxaban at the discretion of the physician within 8 weeks prior to enrollment. Data documentation will occur every 6 (± 90 days) and 12 months (± 90 days) from the start of edoxaban treatment. Patient visits will be conducted according to regular clinical care and should not be influenced by the foreseen data documentation time points.

Ages

80 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * NVAF participants aged ≥ 80 years old * Participants who are determined to be prescribed with edoxaban at the discretion of the physician within 8 weeks prior to enrollment according to Package information * Participants who can return to the site in person for face-to-face visits * Written informed consent for participation in the study (ICF) Exclusion Criteria: * Planning to participate or simultaneously participating in any interventional study * Life expectancy \< 1 year No influence on prescribing behavior as participants will only be included in the study after the physicians have made the clinical decision to prescribe edoxaban.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Catholic University of Korea Daejeon St. Mary's Hospital

    Daejeon, 34943, South Korea

  • Catholic University of Korea Seoul St. Mary's Hospital

    Seoul, 06591, South Korea

  • Catholic University of Korea St. Vincent's Hospital

    Suwon, 16247, South Korea

  • Chonnam Natinal University Hospital

    Gwangju, 61469, South Korea

  • Chosun University Hospital

    Gwangju, 61453, South Korea

  • Chung-Ang University Hosptial

    Seoul, 06973, South Korea

  • Chungnam University Hospital

    Daejeon, 35015, South Korea

  • Dankook University Hospital

    Cheonan, 31116, South Korea

  • Dong-A University Hospital

    Busan, 49201, South Korea

  • Ewha Womans University Seoul Hospital

    Seoul, 07804, South Korea

  • Gachon University Gil Medical Center

    Incheon, 21565, South Korea

  • Gangnam Severance Hospital

    Seoul, 06273, South Korea

  • Gyeongsang National University Hospital

    Jinju, 52727, South Korea

  • Kangbuk Samsung Hospital

    Seoul, 03181, South Korea

  • Kangwon National University Hospital

    Chuncheon, 24289, South Korea

  • Keimyung University Dongsan Medical Center

    Daegu, 41931, South Korea

  • Korea University Anam Hospital

    Seoul, 02841, South Korea

  • Korea University Ansan Hospital

    Ansan, 15355, South Korea

  • Korea University Guro Hospital

    Seoul, 08308, South Korea

  • Korea Veterans Health Medical Center

    Seoul, 05368, South Korea

  • KyungHee University Hospital at GangDong

    Seoul, 05278, South Korea

  • National Health Insurance Service Ilsan Hospital

    Goyang, 10444, South Korea

  • Pusan National University Hospital

    Busan, 49241, South Korea

  • Samsung Changwon Center

    Changwon, 51353, South Korea

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital

    Seoul, 03722, South Korea

  • Soonchunhyang University Hospital

    Cheonan, 31151, South Korea

  • Ulsan University Hospital

    Ulsan, 44033, South Korea

  • Wonju Severance Christian Hospital

    Wŏnju, 26426, South Korea

  • Wonkwang University Hospital

    Iksan, 54538, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.